Literature DB >> 26254478

Prediction of life expectancy in patients with spinal epidural metastasis.

Ronald H M A Bartels1, Godard de Ruiter1, Ton Feuth1, Mark P Arts1.   

Abstract

BACKGROUND: The treatment of spinal epidural metastasis is multidisciplinary and usually involves a team of medical oncologists, radiologists, radiotherapists, and spinal surgeons. Life expectancy is one of the factors considered when deciding whether surgery is warranted. Because expert estimates of life expectancy are generally not reliable, a prediction model is needed. Here, we temporally validated a model that was previously validated geographically.
METHODS: The records of 110 consecutive patients who were referred with a spinal epidural metastasis were collected prospectively from 2009 to 2013 in order to validate the model, which was published in 2011. The actual and estimated life expectancies were represented graphically, and calibration and discrimination were determined. The calibration slope, Harrell's c-index, D, and R2D were calculated. Hazard ratios in the derivation set of 2011 were compared with the validation set. Misspecification was determined using the joint test for β*.
RESULTS: The calibration slope was 0.64 ± 0.15 (95% CI: 0.34-0.94), Harrell's c-index was 0.72, D was 1.08, and R2D was 0.22, indicating slightly worse discrimination in the derivation set. The joint test for β* = 0 was statistically significant and indicated misspecification; however, this misspecification was attributed entirely to the surgical group.
CONCLUSIONS: We validated a prediction model for surgical decision making, showing that the model's overall performance is good. Based on these results, this model will help clinicians to decide whether to offer surgery to patients with spinal epidural metastasis.
© The Author(s) 2015. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  life expectancy; prediction; spinal epidural metastasis; treatment

Mesh:

Year:  2015        PMID: 26254478      PMCID: PMC4677416          DOI: 10.1093/neuonc/nov149

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  16 in total

1.  Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial.

Authors:  Roy A Patchell; Phillip A Tibbs; William F Regine; Richard Payne; Stephen Saris; Richard J Kryscio; Mohammed Mohiuddin; Byron Young
Journal:  Lancet       Date:  2005 Aug 20-26       Impact factor: 79.321

2.  External validation of a model to predict the survival of patients presenting with a spinal epidural metastasis.

Authors:  Ronald H M A Bartels; Ton Feuth; Dirk Rades; Rune Hedlund; Carlos Villas; Yvette van der Linden; Wolgang Börm; Arnoud Kappelle; Richard W M van der Maazen; J André Grotenhuis; André L M Verbeek
Journal:  Cancer Metastasis Rev       Date:  2011-06       Impact factor: 9.264

3.  Prediction of survival in patients with metastases in the spinal column: results based on a randomized trial of radiotherapy.

Authors:  Yvette M van der Linden; Sander P D S Dijkstra; Ernest J A Vonk; Corrie A M Marijnen; Jan Willem H Leer
Journal:  Cancer       Date:  2005-01-15       Impact factor: 6.860

Review 4.  Surgery insight: current management of epidural spinal cord compression from metastatic spine disease.

Authors:  Timothy F Witham; Yevgeniy A Khavkin; Gary L Gallia; Jean-Paul Wolinsky; Ziya L Gokaslan
Journal:  Nat Clin Pract Neurol       Date:  2006-02

5.  Surgical strategy for spinal metastases.

Authors:  K Tomita; N Kawahara; T Kobayashi; A Yoshida; H Murakami; T Akamaru
Journal:  Spine (Phila Pa 1976)       Date:  2001-02-01       Impact factor: 3.468

Review 6.  How accurate are physicians' clinical predictions of survival and the available prognostic tools in estimating survival times in terminally ill cancer patients? A systematic review.

Authors:  E Chow; T Harth; G Hruby; J Finkelstein; J Wu; C Danjoux
Journal:  Clin Oncol (R Coll Radiol)       Date:  2001       Impact factor: 4.126

7.  Accuracy of survival prediction by palliative radiation oncologists.

Authors:  Edward Chow; Lori Davis; Tony Panzarella; Charles Hayter; Ewa Szumacher; Andrew Loblaw; Rebecca Wong; Cyril Danjoux
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-03-01       Impact factor: 7.038

8.  Scoring system for the preoperative evaluation of metastatic spine tumor prognosis.

Authors:  Y Tokuhashi; H Matsuzaki; S Toriyama; H Kawano; S Ohsaka
Journal:  Spine (Phila Pa 1976)       Date:  1990-11       Impact factor: 3.468

9.  Accuracy of the revised Tokuhashi score in predicting survival in patients with metastatic spinal cord compression (MSCC).

Authors:  N A Quraishi; S R Manoharan; G Arealis; A Khurana; S Elsayed; K L Edwards; B M Boszczyk
Journal:  Eur Spine J       Date:  2013-01-18       Impact factor: 3.134

10.  Prognostic factors associated with survival in patients with symptomatic spinal bone metastases: a retrospective cohort study of 1,043 patients.

Authors:  Laurens Bollen; Yvette M van der Linden; Willem Pondaag; Marta Fiocco; Bas P M Pattynama; Corrie A M Marijnen; Rob G H H Nelissen; Wilco C Peul; P D Sander Dijkstra
Journal:  Neuro Oncol       Date:  2014-07       Impact factor: 12.300

View more
  2 in total

Review 1.  Symptomatic spinal metastasis: A systematic literature review of the preoperative prognostic factors for survival, neurological, functional and quality of life in surgically treated patients and methodological recommendations for prognostic studies.

Authors:  Anick Nater; Allan R Martin; Arjun Sahgal; David Choi; Michael G Fehlings
Journal:  PLoS One       Date:  2017-02-22       Impact factor: 3.240

2.  Survival after surgery for spinal metastases: a population-based study.

Authors:  Kunal Bhanot; Jessica Widdifield; Anjie Huang; J Michael Paterson; David B Shultz; Joel Finkelstein
Journal:  Can J Surg       Date:  2022-08-04       Impact factor: 2.840

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.